Patents by Inventor Walter Spevak

Walter Spevak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8859541
    Abstract: 6-Alkynylpyridines which are SMAC mimetics and are useful as medicaments for the treatment of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The following compounds are exemplary: methyl 5-[6-[[2-(methylamino)propanoyl]amino]-2-[2-(3-methylphenyl)ethynyl]pyridin-3-yl]-pyridine-3-carboxylate and 2-(methylamino)-N-[5-(2-methylimidazo[1,2-a]pyridin-3-yl)-6-[2-(1-methyl-2-oxoquinolin-6-yl)-ethynyl]pyridin-2-yl]propanamid.
    Type: Grant
    Filed: February 19, 2013
    Date of Patent: October 14, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ulrich Reiser, Gerd Bader, Walter Spevak, Andreas Steffen, Alastair L. Parkes
  • Publication number: 20130225567
    Abstract: 5-alkynyl-pyridine of general formula (I) their use as SMAC mimetics, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R5 have the meanings given in the claims and in the specification.
    Type: Application
    Filed: February 19, 2013
    Publication date: August 29, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Ulrich REISER, Gerd BADER, Walter SPEVAK, Andreas STEFFEN, Alastair L. PARKES
  • Patent number: 8420630
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: April 16, 2013
    Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
  • Patent number: 8203001
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1, M1, L1 and Q are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or anomalous cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: June 19, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ulrich Reiser, Peter Ettmayer, Oliver Kraemer, Peter Sennhenn, Walter Spevak
  • Publication number: 20100152167
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Application
    Filed: February 24, 2010
    Publication date: June 17, 2010
    Applicants: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.
    Inventors: Georg DAHMANN, Frank HIMMELSBACH, Bernd KRIST, Martin LENTER, Alexander PAUTSCH, Gisela SCHNAPP, Martin STEEGMAIER, Helmut WITTNEBEN, Anthony S. PROKOPOWICZ, Walter SPEVAK, Andreas SCHOOP, Steffen STEURER
  • Patent number: 7709480
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: May 4, 2010
    Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
  • Publication number: 20090258857
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1, M1, L1 and Q are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell proliferation, and the use thereof for preparing a pharmaceutical composition with the above-mentioned properties.
    Type: Application
    Filed: June 13, 2007
    Publication date: October 15, 2009
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Ulrich Reiser, Peter Ettmayer, Oliver Kraemer, Peter Sennhenn, Walter Spevak
  • Publication number: 20090186901
    Abstract: The present invention relates to new heterocyclic compounds of general formula (1) wherein the groups R1 to R7, k, X and Y have the meanings given in the claims and specification, the isomers and salts thereof as well as the use thereof as medicaments. Background to the invention WO 01/36423 describes 3,4-dihydrospiro[chromene-2,4?-piperidine] derivatives for treating diseases of the central nervous system. Spirocyclic heterocycles as ?-opioid receptor ligands for treating pain and anxiety states as well as diseases of the gastrointestinal tract are known from WO 2005/033073. The aim of the present invention is to indicate new active substances which can be used for the prevention and/or treatment of diseases characterised by excessive or abnormal cell proliferation.
    Type: Application
    Filed: May 3, 2007
    Publication date: July 23, 2009
    Inventors: Ulrich Reiser, Oliver Kraemer, Peter Sennhenn, Walter Spevak
  • Patent number: 7173028
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: February 6, 2007
    Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony S. Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
  • Patent number: 7166615
    Abstract: Indolinones of general formula I which are inhibitors of cell proliferation, particularly of tumor cells, and inhibitors of protein kinases.
    Type: Grant
    Filed: August 22, 2003
    Date of Patent: January 23, 2007
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rainer Walter, Armin Heckel, Gerald Roth, Joerg Kley, Gisela Schnapp, Martin Lenter, Jacobus Van Meel, Walter Spevak, Ulrike Weyer-Czernilofsky
  • Patent number: 7160901
    Abstract: Indolinones of general formula I which are inhibitors of cell proliferation, particularly of tumor cells, and inhibitors of protein kinases.
    Type: Grant
    Filed: August 22, 2003
    Date of Patent: January 9, 2007
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rainer Walter, Armin Heckel, Gerald Roth, Joerg Kley, Gisela Schnapp, Martin Lenter, Jacobus Van Meel, Walter Spevak, Ulrike Weyer-Czernilofsky
  • Publication number: 20070004684
    Abstract: The present invention encompasses compounds of general formula (1) wherein R2 to R5 and X are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: June 8, 2006
    Publication date: January 4, 2007
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Peter Sennhenn, Andreas Mantoulidis, Matthias Treu, Ulrike Tontsch-Grunt, Walter Spevak, Darryl McConnell, Andreas Schoop, Ralph Brueckner, Albrecht Jacobi, Ulrich Guertler, Gisela Schnapp, Christian Klein, Frank Himmelsbach, Alexander Pautsch, Bodo Betzmeier, Lars Herfurth, Juergen Mack, Dieter Wiedenmayer, Gerd Bader, Ulrich Reiser
  • Publication number: 20060100211
    Abstract: The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
    Type: Application
    Filed: December 21, 2005
    Publication date: May 11, 2006
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Georg Dahmann, Frank Himmelsbach, Bernd Krist, Martin Lenter, Alexander Pautsch, Gisela Schnapp, Martin Steegmaier, Helmut Wittneben, Anthony Prokopowicz, Walter Spevak, Andreas Schoop, Steffen Steurer
  • Patent number: 6855710
    Abstract: The present invention relates to new substituted indolinones of general formula wherein X and R1 to R5 are defined as in claim 1, the isomers and the salts thereof which have valuable properties. The above compounds of general formula I wherein R1 denotes a hydrogen atom, a C1-3-alkyl group or a prodrug group have valuable pharmacological properties, particularly an inhibiting effect on various kinases, on viral cyclin and on receptor tyrosine kinases, and the other compounds of the above general formula I wherein R1 does not represent a hydrogen atom, a C1-3-alkyl group or a prodrug group are valuable intermediate products for the preparation of the abovementioned compounds.
    Type: Grant
    Filed: September 19, 2003
    Date of Patent: February 15, 2005
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Rainer Walter, Wolfgang Grell, Armin Heckel, Frank Himmelsbach, Wolfgang Eberlein, Gerald Roth, Jacobus C.A. van Meel, Norbert Redemann, Walter Spevak, Ulrike Tontsch-Grunt, Thomas von Rueden
  • Publication number: 20050009898
    Abstract: The present invention relates to substituted indolinones of general formula wherein R1 to R6 and X are defined as in claim 1, the isomers and the salts thereof, in particular the physiologically acceptable salts thereof which have valuable pharmacological properties, especially an inhibitory effect on various receptor-tyrosine kinases, and cycline/CDK complexes as well as on the proliferation of endothelial cells and various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
    Type: Application
    Filed: July 27, 2004
    Publication date: January 13, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Gerald Roth, Armin Heckel, Rainer Walter, Ulrike Tontsch-Grunt, Walter Spevak, Jacobus Van Meel
  • Patent number: 6794395
    Abstract: The present invention relates to substituted indolinones of general formula wherein R1 to R6 and X are defined as in claim 1, the isomers and the salts thereof, in particular the physiologically acceptable salts thereof which have valuable pharmacological properties, especially an inhibitory effect on various receptor-tyrosine kinases, and cycline/CDK complexes as well as on the proliferation of endothelial cells and various tumor cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
    Type: Grant
    Filed: July 22, 2002
    Date of Patent: September 21, 2004
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Gerald Juergen Roth, Armin Heckel, Rainer Walter, Ulrike Tontsch-Grunt, Walter Spevak, Jacobus C. A. Van Meel
  • Patent number: 6762180
    Abstract: Indolinones of the formula having an inhibitory effect on receptor tyrosine kinases and cyclin/CDK complexes, as well as on the proliferation of endothelial cells and various tumor cells. Exemplary are: (a) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-ethoxycarbonyl-2-indolinone, (b) 3-Z-[(1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-carbamoyl-2-indolinone, and (c) 3-Z-[1-(4-(piperidin-1-yl-methyl)-anilino)-1-phenyl-methylene]-6-metboxycarbonyl-2-indolinone.
    Type: Grant
    Filed: October 3, 2000
    Date of Patent: July 13, 2004
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Gerald Juergen Roth, Armin Heckel, Rainer Walter, Jacobus Van Meel, Norbert Redemann, Ulrike Tontsch-Grunt, Walter Spevak, Frank Hilberg
  • Publication number: 20040058978
    Abstract: The present invention relates to new substituted indolinones of general formula 1
    Type: Application
    Filed: September 19, 2003
    Publication date: March 25, 2004
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Rainer Walter, Wolfgang Grell, Armin Heckel, Frank Himmelsbach, Wolfgang Eberlein, Gerald Roth, Jacobus C. A. van Meel, Norbert Redemann, Walter Spevak, Ulrike Tontsch-Grunt, Thomas von Rueden
  • Publication number: 20040044222
    Abstract: Indolinones of general formula I 1
    Type: Application
    Filed: August 22, 2003
    Publication date: March 4, 2004
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Rainer Walter, Armin Heckel, Gerald Roth, Joerg Kley, Gisela Schnapp, Martin Lenter, Jacobus Van Meel, Walter Spevak, Ulrike Weyer-Czernilofsky
  • Publication number: 20040044053
    Abstract: Indolinones of general formula I 1
    Type: Application
    Filed: August 22, 2003
    Publication date: March 4, 2004
    Applicant: Boehringer Ingelheim Pharma KG
    Inventors: Rainer Walter, Armin Heckel, Gerald Roth, Joerg Kley, Gisela Schnapp, Martin Lenter, Jacobus Van Meel, Walter Spevak, Ulrike Weyer-Czernilofsky